Author: Ravi Shankar

• Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows.

Zymeworks will host a conference call with investors and the general public at 8:30 am ET on Monday, September 28, to discuss the final transaction details of the acquisition. Dial-in details and webcast link are available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations. A replay of the webcast will be available within 24 hours following the conclusion of the call and will remain archived for a limited period.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks’ asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI^® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera^® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable Zymeworks to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated benefits of the acquisition of Theravance Biopharma; the anticipated benefits of the financing in connection with the closing of the acquisition; anticipated milestone payments; completion of Theravance’s previously announced organizational restructuring; Zymeworks’ flexibility to invest in its R&D pipeline and pursue strategic opportunities while returning capital to stockholders; future growth of YUPELRI® sales and future royalty payments; contingent milestone payments due to Theravance Biopharma from the sale of Theravance Biopharma’s TRELEGY® royalty interests; Zymeworks’ expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks’ and its partners’ clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, or the negative version of these words and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct.

Factors that could cause Zymeworks’ actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: financial closing procedures, final adjustments, and other developments; risks related to the financing in connection with the closing of the acquisition; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; uncertainties regarding the commercial success of YUPELRI^® and TRELEGY^®; the anticipated benefits of the acquisition may not be realized or will not be realized within the expected time period; TRELEGY^® may not achieve anticipated sales resulting in sales milestones not being met; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; Ziihera^® may not be successfully commercialized; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the U.S. Securities and Exchange Commission and System for Electronic Document Analysis and Retrieval+ (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com

Court Vacates FDA Determinations That AXIOFILL Is Not Minimally Manipulated and Should Be Classified as a Biological Product

Order Further Holds That Minimal-Manipulation Analysis Must Consider Tissue Characteristics Relevant to Reconstruction, Repair or Replacement in the Recipient

MARIETTA, Ga., Sept. 23, 2026 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation challenging the U.S. Food and Drug Administration’s (“FDA”) regulatory classification of AXIOFILL, the Company’s human placental-derived extracellular matrix particulate product.

The Court vacated FDA’s determination that AXIOFILL is not a Section 361 HCT/P because it is more than minimally manipulated and FDA’s determination that AXIOFILL should be classified as a biological product rather than a medical device. The Court remanded both matters to FDA for further consideration consistent with its order.

“This ruling favorably addresses the central issues of this matter. We are pleased the Court found that the FDA erred in its interpretation of the minimal-manipulation regulation and that the agency did not adequately explain the reasoning behind its divergent classification of AXIOFILL compared with similar products available on the market,” stated Joseph H. Capper, Chief Executive Officer of MIMEDX. “We continue to believe that AXIOFILL meets the requirements for classification as a Section 361 HCT/P, and we look forward to engaging constructively with FDA as it reconsiders the matter consistent with the Court’s order.   Since its launch in 2022, AXIOFILL has demonstrated an impeccable safety profile and has helped countless patients navigate the surgical healing process.”

In addressing whether AXIOFILL qualifies as a Section 361 HCT/P, the Court held that FDA had incorrectly interpreted its minimal-manipulation regulation by focusing on the placental disc’s function in the donor—specifically, its function as a selective barrier between the fetal and maternal circulatory systems. The Court concluded that the applicable regulation instead requires FDA to consider the original characteristics of the tissue that are relevant to its utility for reconstruction, repair or replacement in the recipient.

The Court also vacated FDA’s determination that to the extent AXIOFILL is not a Section 361 HCT/P, it is a biological product rather than a device. The Court found that FDA had classified other commercially available human-derived particulate products, similar to AXIOFILL, as medical devices without adequately explaining why AXIOFILL should be treated differently.   The Court concluded that FDA’s classification of AXIOFILL as a biological product was “arbitrary and capricious” because the agency had not provided “a reasonable explanation or record of evidence” supporting this disparate treatment.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

PHILADELPHIA, PA, Sept. 23, 2026 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ: FIVE), the trend-right, extreme-value brand for the kid and the kid in all of us, today announced the appointment of Scott Settersten, former Chief Financial Officer of Ulta Beauty, to its Board of Directors and the Audit Committee of its Board of Directors, effective September 21, 2026. In connection with Mr. Settersten’s appointment, Five Below’s Board increased to ten directors.

“Scott is a highly respected finance leader with a proven track record of scaling a high-growth retail business while maintaining strong financial discipline,” said Mike Devine, Chair of the Five Below Board. “His deep financial and operational expertise will be a valuable addition to our Board, and we look forward to drawing on Scott’s experience as we execute on our significant growth opportunity and drive long-term value for our stakeholders.”

Mr. Settersten served as the Chief Financial Officer of Ulta Beauty from 2012 until his retirement in March 2024, where he oversaw the company’s finance, accounting, tax, treasury, procurement, internal audit, investor relations, loss prevention and real estate teams. Mr. Settersten also spent 15 years with PricewaterhouseCoopers LLP as a certified public accountant in the assurance and risk management practices. In addition, he served as a director and member of the audit committee of Kimball International from July 2020 to June 2023.

“I am honored to join the Five Below Board at such an exciting time in the company’s evolution,” said Mr. Settersten. “Five Below is one of the most compelling growth stories in retail with a unique value proposition and target customer,” Mr. Settersten continued. “I look forward to working with the Board and leadership team to build on the company’s momentum and execute its long-term growth strategy to create lasting value for shareholders.”

About Five Below:
Five Below is a leading growth retailer offering trend-right, extreme value, high-quality products loved by the kid and the kid in all of us. We believe life is better when customers are free to “let go & have fun” in an amazing experience filled with unlimited possibilities. With most items priced between $1 and $5 and some extreme value items priced beyond $5, Five Below makes it easy to say YES! to the newest, coolest stuff across awesome Five Below worlds: Candy, Style, Party, Room, Create, Tech, Sports and New & Now. Founded in 2002 and headquartered in Philadelphia, Pennsylvania, Five Below today has over 2,000 stores in 47 states. For more information, please visit www.fivebelow.com or follow @fivebelow on TikTok, Instagram, Facebook, and YouTube.

Investor Contact:
Five Below, Inc.
Christiane Pelz, Vice President, Investor Relations
InvestorRelations@fivebelow.com

BEVERLY, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) — ATN International, Inc. (Nasdaq: ATNI) announced that its Board of Directors has declared a quarterly dividend of $0.29 per share, payable on October 9, 2026, on all common shares outstanding to stockholders of record as of October 3, 2026.

About ATN

ATN International, Inc. (Nasdaq: ATNI), headquartered in Beverly, Massachusetts, is a provider of digital infrastructure and communications services in the United States and internationally, including the Caribbean region, with a focus on rural and remote markets with a growing demand for infrastructure investments. The Company’s operating subsidiaries today primarily provide: (i) advanced wireless and wireline connectivity to residential, business and government customers, including a range of high-speed Internet and data services, fixed and mobile wireless solutions, and video and voice services; and (ii) carrier and enterprise communications services, such as terrestrial and submarine fiber optic transport, and communications tower facilities. For more information, please visit www.atni.com. 

Company Contact:		Investor Relations Contact:
Michele Satrowsky		Joe Noyons or Kelley Buchhorn
SVP, Head of IR & Treasury		Three Part Advisors, LLC
ir@atni.com		jnoyons@threepa.com; kbuchhorn@threepa.com

George Boyan to Become Chief Executive Officer on April 1, 2027; Hughes to Continue Serving on Company and Bank Board

CLINTON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — Unity Bancorp, Inc. (NASDAQ: UNTY) and its wholly owned subsidiary, Unity Bank, today announced that James A. Hughes will retire from his position as Chief Executive Officer of the Company and the Bank effective March 31, 2027, following more than 26 years of dedicated service. Mr. Hughes will continue to serve on the Boards of Directors of both Unity Bancorp, Inc. and Unity Bank following his retirement.

As part of a deliberate, multi-year succession planning process, the Boards unanimously selected current President George Boyan to succeed Mr. Hughes as Chief Executive Officer effective April 1, 2027. Mr. Boyan will continue to serve as President of the Company and the Bank, a position he has held since January 1, 2026. During his tenure with Unity, he has held key executive leadership responsibilities and has been a key contributor to the Company’s growth, commercial banking expansion, operational performance, and talent development initiatives.

During Mr. Hughes’ tenure, Unity achieved significant growth, enhanced shareholder value, expanded its presence across New Jersey and Pennsylvania, strengthened its commercial and retail banking capabilities, and established itself as a leading community banking institution. Under his leadership, Unity remained committed to relationship-based banking while delivering strong financial performance and fostering a culture centered on customer service, integrity, accountability, and community involvement.

“Jim Hughes has left an indelible mark on Unity.” said David D. Dallas, Chairman of the Board. “His vision, integrity, and commitment to community banking have shaped our organization and positioned it for long-term success. On behalf of the Boards of Directors, I thank Jim for his extraordinary leadership and more than 26 years of dedicated service to our customers, employees, shareholders, and communities. We are especially pleased that he will continue serving on both Boards, where his experience, judgment, and institutional knowledge will remain invaluable.”

“It has been the privilege of a lifetime to serve Unity, our customers, our shareholders, our employees, and the communities we serve,” said James A. Hughes. “I am incredibly proud of what we have accomplished together over the past 26 years. Unity’s success has always been driven by the dedication of our employees and our commitment to building meaningful relationships with our customers. I have complete confidence in Unity’s future and in George’s ability to lead the organization through its next chapter. I look forward to continuing to support Unity as a member of the Boards of Directors.”

“George is the right leader to guide Unity forward,” said Dallas. “He has a deep understanding of our business, culture, markets, and strategic priorities. His selection reflects the strength of our succession planning process and the Boards’ confidence in Unity’s future. We are confident that George will build upon the strong foundation established under Jim’s leadership while preserving the relationship-based banking model that has been central to Unity’s success.”

“I am honored by the Boards’ confidence and grateful for Jim’s mentorship, leadership, and friendship over the years,” said George Boyan. “Unity has an exceptional team, a strong culture, and a proven relationship-based banking model. I look forward to working alongside our employees, management team, and Board as we continue delivering exceptional service to our customers, supporting our communities, and creating long-term value for our shareholders”

The Board emphasized that the leadership transition reflects a well-planned succession process and positions the Company for continued growth, while preserving the relationship-based community banking model that has defined Unity’s success.

James Hughes’ Legacy at Unity
Throughout his 26-year career with Unity Bank and Unity Bancorp Inc, Jim Hughes played a pivotal role in transforming the organization into one of the nation’s premier community banking institutions. Under his leadership, Unity remained committed to its relationship-driven banking model while delivering sustained growth, strong financial performance, and long-term value creation for shareholders.

Among the many accomplishments achieved during Mr. Hughes’ tenure:

• Played a pivotal role in building Unity into one of the nation’s standout community banking institutions, delivering exceptional long-term growth in assets, earnings, and shareholder value while maintaining the Bank’s commitment to customer service and supporting local communities.
• Grew total assets from approximately $356.0 million to $3.2 billion.
• Increased shareholder value through disciplined capital management and consistent earnings performance.
• Expanded Unity’s footprint to 22 branch locations across New Jersey and Pennsylvania.
• Increased book value per share over 8.5x since his start date.
• Delivered compounded annualized shareholder returns of approximately 17.0% during his leadership tenure.
• Grew the Company’s market capitalization from approximately $7.4 million to more than $575 million.
• Strengthened Unity’s position as a leading community banking franchise known for exceptional customer service, local decision-making, and strong asset quality.

About Unity Bancorp, Inc.
Unity Bancorp, Inc. (NASDAQ: UNTY) is the parent company of Unity Bank, a financial services organization based in Clinton, New Jersey. Unity Bank operates 22 branches across New Jersey and the Lehigh Valley, Pennsylvania, offering community-focused commercial banking services, including deposit accounts, loans, and digital services. For details, visit unitybank.com or call 800-618-BANK (800-618-2265). Unity Bank is a member of the Federal Deposit Insurance Corporation (FDIC). To learn about FDIC insurance, visit FDIC.gov.

News Media & Financial Analyst Contact:
James Davies
FSVP and Chief Financial Officer
(908) 713-4330

JERSEY CITY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — Verizon today announced a $1 million grant to the Liberty Science Center (LSC) in Jersey City, NJ in conjunction with the launch of Verizon AI Skills for America, a new workforce development initiative equipping workers, small businesses, and educators nationwide with practical AI skills. Unveiled at LSC, the grant will support tech-driven education initiatives and establish interactive programming that introduces visitors to the innovative AI skilling technology that is at the heart of this new national initiative.

To bring this national vision into local communities, Verizon is collaborating with premier educational hubs like LSC, an organization known for sparking lifelong learning and scientific curiosity. This grant will help LSC provide visitors with exposure to Verizon’s new AI training resource to help communities confidently embrace new technology and shape their own futures.

“From Thomas Edison’s laboratories to the breakthroughs at Bell Labs, New Jersey has a proud history of innovations that changed the world,” said Governor Sherrill. “Liberty Science Center keeps that spirit of discovery alive, and this investment from Verizon will give students and workers practical skills they can turn into opportunities. By preparing more New Jerseyans for good-paying jobs, we will keep our state at the forefront of innovation.”

“As a company with a strong footprint in New Jersey, Verizon is deeply committed to supporting the communities we call home, and our longstanding partnership with Liberty Science Center is a cornerstone of that commitment,” said Donna Epps, Chief Responsible Business Officer of Verizon. “Verizon and LSC have a shared vision of empowering the learners and leaders of tomorrow, and we’re excited to work together to create programming that evokes curiosity for new technologies for educators, families and students from across the state.”

This donation represents the latest chapter in the partnership between Verizon and LSC. Verizon is a proud Founding Corporate Sponsor of SciTech Scity, the 30-acre innovation campus currently under development by LSC, aimed at bringing together scientists, entrepreneurs, and students to pioneer new technologies.

“Verizon has been a steadfast partner in our mission to inspire the next generation of scientists and engineers,” said Paul Hoffman, President and CEO of Liberty Science Center. “From their early support as a founding sponsor of SciTech Scity to this generous new grant, Verizon understands that building prepared communities and empowering individuals starts by working at the local level. We look forward to creating a program that allows our guests to experience the power of this technology firsthand in an accessible, hands-on environment.”

To learn more about Verizon’s national workforce efforts, visit verizon.com/aiskillsforamerica. To plan a visit to the Liberty Science Center, visit lsc.org.

This announcement was originally published by Verizon. Read the original press release.

About Verizon
Verizon Communications Inc. (NYSE, Nasdaq: VZ) powers and empowers how its millions of customers live, work and play, delivering on their demand for mobility, reliable network connectivity and security. Headquartered in New York City, serving countries worldwide and nearly all of the Fortune 500, Verizon generated revenues of $138.2 billion in 2025. Verizon’s world-class team never stops innovating to meet customers where they are today and equip them for the needs of tomorrow. For more, visit verizon.com or find a retail location at verizon.com/stores.

About Liberty Science Center
Liberty Science Center (LSC.org) is a 300,000-square-foot, not-for-profit learning center located in Liberty State Park on the Jersey City bank of the Hudson near the Statue of Liberty. Dedicated to inspiring the next generation of scientists and engineers and bringing the power, promise, and pure fun of science and technology to learners of all ages, Liberty Science Center houses the largest planetarium in the Western Hemisphere, 12 museum exhibition halls, a live animal collection with 110 species, giant aquariums, a 3D theater, live simulcast surgeries, a tornado-force wind simulator, K-12 classrooms and labs, and teacher-development programs. More than 280,000 students visit the Science Center each year, and tens of thousands more participate in the Center’s off- site and online programs. Welcoming more than 800,000 visitors annually, LSC is the largest cultural institution in New Jersey and the largest interactive science center in the NYC-NJ metropolitan area.

Media Contact:
Alyssa Forsell
alyssa.forsell@verizon.com

References are made to the stock exchange announcements by AKVA group ASA (AKVA) on 30 June 2026 and 3 August 2026 regarding the merger of Submerged AS (as the non-surviving entity) with AKVA (as the surviving entity).

The merger was completed on 23 September 2026 upon registration of the merger by the Norwegian Register of Business Enterprises.

This information is subject to the disclosure requirements pursuant to section 4.2.4 of Oslo Rule Book II – Issuer Rules, cf. section 5-12 of the Norwegian Securities Trading Act.

Dated: 23 September 2026

AKVA group ASA
Web: www.akvagroup.com

CONTACTS:

Knut Nesse     Chief Executive Officer
Phone:    +47 51 77 85 00
Mobile:    +47 91 37 62 20
E-mail:    knesse@akvagroup.com 

Ronny Meinkøhn     Chief Financial Officer

Phone:           +47 51 77 85 00
Mobile:          +47 98 20 67 76
E-mail:          rmeinkohn@akvagroup.com

Collaboration features high-speed SerDes, advanced packaging and SI/PI expertise

SAN JOSE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Today at the TSMC 2026 North America Open Innovation Platform^® (OIP) Ecosystem Forum, Alchip Technologies presented a technical paper with Synopsys on how AI data center ASICs can overcome increasingly stringent bandwidth requirements as scale-up and out interfaces become critical to next‑generation system architectures. This approach brings together Synopsys 224G PHY IP with Alchip’s advanced packaging and signal integrity/power integrity (SI/PI) expertise in a protocol-agnostic physical design.

Breaking Through the Bandwidth Wall

As AI accelerators scale to meet growing performance demands, moving data on and off the chip fast enough becomes one of the hardest problems in the design. At 224 Gbps SerDes speeds, the presentation addressed several key physical design challenges:

• Die-edge congestion and escape routing complexity, along with signal and power integrity constraints across both die and package
• Limited die-edge real estate and asymmetric constraints between East/West (E/W) and North/South (N/S) edges
• Dense package substrate breakout requirements that must be met without degrading channel performance

The collaboration overcame these barriers through a coordinated optimization of escape routing, die-edge utilization, and package breakout — carefully balancing signal and power integrity requirements to maintain overall system performance. Differentiated handling of E/W and N/S die edges further ensured that maximum bandwidth per millimeter of die-edge beachfront was achieved at max reach, consistently across all die edges.

Building on this work, the analysis extended to E/W package breakout techniques needed to sustain 1.6 terabits per second (Tbps) of networking bandwidth, highlighting key routing density and SI/PI considerations at the substrate level. The resulting protocol-agnostic, forward-scalable physical design approach provides a foundation that can ultimately support 448G SerDes implementations.

Pushing Bandwidth Density to Its Physical Limits

Using this collaborative methodology, engineers achieved chip‑to‑chip interconnect bandwidth density approaching theoretical physical limits. This demonstrates the feasibility of ultra‑high‑density 224G scale‑up interconnect implementations within realistic die edge and package constraints.

These results point to broader implications for data center design, as AI accelerators and high‑performance networking ASICs continue to scale, maximizing bandwidth per millimeter directly impacts system throughput and scalability.

About Alchip

Alchip Technologies Ltd., founded in 2003 and headquartered in Taipei, Taiwan, is a leading global High-Performance Computing and AI infrastructure ASIC provider of IC and packaging design, and production services for companies developing complex and high-volume ASICs and SoCs.  Alchip provides faster time-to-market and cost-effective solutions for SoC design at mainstream and advanced process technology. Alchip has built its reputation as a high-performance ASIC leader through its advanced 2.5D/3D CoWoS packaging, chiplet design, and manufacturing management. Customers include global leaders in artificial intelligence, high-performance computing, supercomputing, mobile communications, entertainment device, networking equipment, and other electronic product categories. Alchip is listed on the Taiwan Stock Exchange (TWSE: 3661).

For more information, please visit our website: http://www.alchip.com

CONTACT: Charles Byers
Alchip Technologies
+ (408)-310-9244
chuck_byers@alchip.com

WHITE PLAINS, N.Y., Sept. 23, 2026 (GLOBE NEWSWIRE) — NorthEast Community Bancorp, Inc. (the “Company”) (Nasdaq: NECB) announced today that its Board of Directors has declared a quarterly cash dividend of $0.25 per common share. The dividend will be paid on or about November 13, 2026 to shareholders of record as of the close of business on October 9, 2026.  

About NorthEast Community Bancorp, Inc.

NorthEast Community Bancorp, headquartered at 325 Hamilton Avenue, White Plains, New York 10601, is the holding company for NorthEast Community Bank, which conducts business through its eleven branch offices located in Bronx, New York, Orange, Rockland, and Sullivan Counties in New York and Essex, Middlesex, and Norfolk Counties in Massachusetts and three loan production offices located in New City, New York, White Plains, New York, and Danvers, Massachusetts. For more information about NorthEast Community Bancorp and NorthEast Community Bank, please visit www.necb.com.

Cautionary Note About Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements include statements regarding anticipated future events and can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as “believe,” “expect,” “anticipate,” “estimate,” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause actual results to differ materially from expected results include, but are not limited to, changes in market interest rates, regional and national economic conditions (including higher inflation and its impact on regional and national economic conditions), legislative and regulatory changes, monetary and fiscal policies of the United States government, including policies of the United States Treasury and the Federal Reserve Board, the quality and composition of the loan or investment portfolios, demand for loan products, decreases in deposit levels necessitating increased borrowing to fund loans and securities, competition, demand for financial services in NorthEast Community Bank’s market area, changes in the real estate market values in NorthEast Community Bank’s market area, the impact of failures or disruptions in or breaches of the Company’s operational or security systems, data or infrastructure, or those of third parties, including as a result of cyberattacks or campaigns, and changes in relevant accounting principles and guidelines. Additionally, other risks and uncertainties may be described in our annual and quarterly reports filed with the U.S. Securities and Exchange Commission (the “SEC”), which are available through the SEC’s website located at www.sec.gov. These risks and uncertainties should be considered in evaluating any forward-looking statements and undue reliance should not be placed on such statements. Except as required by applicable law or regulation, the Company does not undertake, and specifically disclaims any obligation, to release publicly the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of the statements or to reflect the occurrence of anticipated or unanticipated events.

CONTACT:		Kenneth A. Martinek
		Chairman and Chief Executive Officer
PHONE:		(914) 684-2500

Clarification intended to provide investors and market participants with accurate, up-to-date information based on the Company’s official filings with the U.S. Securities and Exchange Commission

MACAU, Sept. 23, 2026 (GLOBE NEWSWIRE) — Zenta Group Company Limited (“Zenta Group” or the “Company”) (Nasdaq: ZTG) today issued a clarification regarding the number of its ordinary shares issued and outstanding, following the share issuance completed in connection with the closing of the Company’s acquisition of ZentoAI Intelligent Technology Company Limited (“ZentoAI”) on September 11, 2026.

The Company is providing this clarification because it has become aware that certain third-party market-data and trading platforms continue to display an older share count that does not reflect that issuance.

Current Shares Outstanding

As reported in the Company’s Report of Foreign Private Issuer on Form 6-K furnished to the U.S. Securities and Exchange Commission (the “SEC”) on September 16, 2026, as of the closing of the ZentoAI acquisition the Company had 24,087,179 ordinary shares issued and outstanding, consisting of:

• 17,719,499 Class A ordinary shares, par value US$0.001 per share, each carrying one vote; and
• 6,367,680 Class B ordinary shares, par value US$0.001 per share, each carrying fifty votes.

The Company’s Class A ordinary shares are the only class of the Company’s shares listed and traded, and trade on the Nasdaq Capital Market under the symbol “ZTG.” The Class B ordinary shares are not listed and are convertible, at the option of the holder, into Class A ordinary shares on a one-for-one basis.

Recent Share Issuance

On September 11, 2026, the Company completed its acquisition of 100% of the issued and outstanding shares of ZentoAI. As part of the consideration for the acquisition, the Company issued 12,278,340 Class A ordinary shares to the selling shareholders. That issuance is reflected in the share counts set out above.

Clarification Regarding Third-Party Market Data

The Company has become aware that certain third-party financial-data and trading platforms continue to display a share count for the Company of approximately 11.8 million shares outstanding. That figure corresponds to the total number of the Company’s ordinary shares issued and outstanding immediately prior to the September 11, 2026 issuance described above, and therefore does not reflect that issuance or the Company’s current capital structure.

Third-party platforms obtain, compile, and update share data on their own schedules and according to their own methodologies, and the timing of such updates is outside the Company’s control. The Company is not aware of any basis to suggest that any platform, data provider, broker, or exchange has acted improperly, and this announcement should not be read as any allegation against any of them.

The Company’s SEC filings should be treated as the authoritative source for the Company’s reported share count. Where information displayed on any third-party platform differs from the Company’s SEC filings, investors and market participants should rely on the Company’s SEC filings. Those filings are available free of charge at www.sec.gov and through the Company’s investor relations website at https://ir.zenta.mo. The Form 6-K furnished on September 16, 2026 is available at https://www.sec.gov/Archives/edgar/data/2011458/000149315226042820/form6-k.htm.

The Company is taking steps to communicate its updated share information to relevant market-data providers, with the aim of improving consistency and transparency of the information available to investors. The timing and manner in which any provider updates the information it displays remain outside the Company’s control.

A Note on Terminology

The figures set out in this announcement refer to the Company’s ordinary shares issued and outstanding as of the closing of the ZentoAI acquisition on September 11, 2026, comprising both Class A ordinary shares and Class B ordinary shares. Shares outstanding is a distinct measure from public float, which refers to shares held by non-affiliates, and from fully diluted shares, which reflects the effect of securities convertible into or exercisable for ordinary shares. This announcement does not state a public float figure or a fully diluted share count, and the figures above should not be used as, or in place of, either measure.

About Zenta Group Company Limited

Zenta Group Company Limited is a holding company incorporated in the Cayman Islands, with operations conducted in Macau through its operating subsidiaries. The Company is a professional services provider in Macau engaged in the provision of industrial park consultation services and business investment consultation services, and in the sale of fintech products and services. Its clients are primarily from the Greater Bay Area of China. Following the Company’s acquisition of ZentoAI in September 2026, the Group also provides artificial-intelligence and data platform services to customers in mainland China and Asia.

The Company’s Class A ordinary shares have traded on the Nasdaq Capital Market since September 9, 2025, and trade under the symbol “ZTG.”

For more information, please visit the Company’s investor relations website: https://ir.zenta.mo

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including statements regarding the steps the Company is taking to communicate its updated share information to market-data providers and whether, when, or how any provider may update the information it displays. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations. Investors can identify these forward-looking statements by words or phrases such as “believes,” “expects,” “anticipates,” “intends,” “plans,” “aims,” “will,” “would,” “should,” “could,” “may,” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results, and encourages investors to review the risk factors and other information in the Company’s filings with the SEC, including its Annual Report on Form 20-F for the fiscal year ended September 30, 2025.

CONTACT: For investor and media inquiries, please contact:

Zenta Group Company Limited, Investor Relations, Avenida do Infante D. Henrique, No. 47-53A, Macau Square, 13th Floor, Unit M, Macau 999078, Tel: +853 2840 0625, Email: ir@zenta.mo